| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_45bd7d61856eb66601634184051f634b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_0dfa62adb15b481d6057dd1e31d65fa1
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_4fcaed31afee960c63f0d21e133fab13 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-15
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-343
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-137
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-135
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-55 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-343
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-135
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-55
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-137
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-15 |
| filingDate |
2003-02-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d54fa481efe5f5b0ef7b17c42a0c16e6
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_310aee0857cf8110ed8190209556b0ef |
| publicationDate |
2003-08-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-03063866-A1 |
| titleOfInvention |
Agents which interact with a serotonin transporter for the treatment of cancer |
| abstract |
The present invention relates to a method of inducing cell death in a neoplastic cell expressing a serotonin transporter (SERT) such as Burkitt’s lymphoma cell or a chronic lymphocytic leukaemia cell. The method comprising exposing said neoplastic cell to a therapeutically effective amount of a pharmaceutically active agent which interacts with said SERT, said therapeutically effective amount being sufficient to cause death of said neoplastic cell. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-2959904-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2016062289-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8835506-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2015197839-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/AU-2015279105-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10195207-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/AU-2020200010-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-1797427-A2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-1797427-A4
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11337984-B2 |
| priorityDate |
2002-02-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |